文献速递外周动脉疾病

慢性肢体威胁性缺血膝下旁路术后抗血栓治疗对下肢结局的影响

Effect of postoperative antithrombotic therapy on lower extremity outcomes after infrapopliteal bypass for chronic limb-threatening ischemia.
PubMed 文献 · J Vasc Surg · 2022-01-21

基于Vascular Quality Initiative注册数据库2003至2017年因慢性肢体威胁性缺血行膝下旁路术并链接Medicare索赔数据的1812例患者,按出院抗血栓方案分为单联抗血小板(SAPT)693例、双联抗血小板(DAPT)544例和抗凝联合任何抗血小板(AC+AP)575例。与SAPT相比,DAPT和AC+AP的3年主要不良肢体事件、大截肢、再干预和死亡率均无显著差异,支持现行指南推荐下肢旁路术后使用SAPT。

要点

  • 与SAPT相比,DAPT和AC+AP的3年主要不良肢体事件无显著差异。
  • 3年大截肢、再干预和死亡率在各抗血栓方案间亦无显著差异。
  • 在高龄Medicare人群中,常规使用DAPT或抗凝治疗可能不提供临床获益。

核心结论

  • 与SAPT相比,DAPT和抗凝治疗与接受膝下旁路术的Medicare受益人结局改善无关。
  • 这些发现支持现行指南推荐下肢旁路术后使用SAPT,并提示常规使用DAPT或抗凝治疗可能不提供临床获益。
  • 作者认为需要对相关亚组中各种抗血栓方案的风险和获益进行进一步评估。

研究设计与样本

  • 回顾性队列研究,基于Vascular Quality Initiative注册数据库2003至2017年因慢性肢体威胁性缺血行膝下旁路术并链接Medicare索赔数据的患者。
  • 共纳入1812例患者,中位随访超过2年;按出院抗血栓方案分为SAPT组693例(38%)、DAPT组544例(30%)和AC+AP组575例(32%)。
  • 为减少选择偏倚,分析队列限制在每种抗血栓方案出院比例超过50%的提供者治疗的患者。
  • 采用Kaplan-Meier和Cox回归分析,按抗血栓方案分层,并调整人口学、合并症、临床和手术差异,以中心水平聚类。

主要发现

  • 3年主要不良肢体事件率:DAPT组75%,AC+AP组74%,SAPT组68%。
  • 以SAPT为参照,3年主要不良肢体事件:DAPT组aHR为1.0(95%CI 0.85-1.3,P=0.71),AC+AP组aHR为1.1(95%CI 0.96-1.3,P=0.14),均无显著差异。
  • 3年大截肢:DAPT组aHR为0.98(95%CI 0.72-1.3),AC+AP组aHR为1.3(95%CI 0.96-1.7),均无显著差异。
  • 3年再干预:DAPT组aHR为1.0(95%CI 0.84-1.3),AC+AP组aHR为1.1(95%CI 0.96-1.3),均无显著差异。
  • 3年死亡率:DAPT组aHR为1.1(95%CI 0.88-1.4),AC+AP组aHR为0.95(95%CI 0.74-1.2),均无显著差异。

关键数值与推荐

  • 现行指南推荐因慢性肢体威胁性缺血行血运重建的患者使用单联抗血小板治疗(SAPT)。
  • 与SAPT相比,DAPT和AC+AP的3年主要不良肢体事件、大截肢、再干预和死亡率均无显著差异。

临床怎么用

  • 作者结论支持现行指南推荐下肢旁路术后使用SAPT,并提示常规使用DAPT或抗凝治疗可能不提供临床获益。
  • 作者认为需要对相关亚组中各种抗血栓方案的风险和获益进行进一步评估。

局限性

  • 作者结论指出需要对相关亚组中各种抗血栓方案的风险和获益进行进一步评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Although the current guidelines have recommended single antiplatelet therapy (SAPT) for patients undergoing revascularization for chronic limb-threatening ischemia (CLTI), antithrombotic management has varied by patient and provider. Our aim was to examine the effects of different postoperative antithrombotic regimens on 3-year clinical outcomes after infrapopliteal bypass for CLTI. METHODS: We identified patients who had undergone infrapopliteal bypass for CLTI in the Vascular Quality Initiative (VQI) registry from 2003 to 2017 with linkage to Medicare claims for long-term outcomes. We divided the patients into three cohorts according to the discharge antithrombotic regimen: SAPT (aspirin or clopidogrel), dual antiplatelet therapy (DAPT; aspirin and clopidogrel), or anticoagulation (AC) plus any antiplatelet (AP) agent. To reduce selection bias, we restricted the analysis cohorts to patients treated by providers who discharged >50% of patients with each antithrombotic regimen. Our primary outcome was 3-year major adverse limb events (MALE; major amputation or reintervention). The secondary outcomes included 3-year major amputation, reintervention, and mortality. We used Kaplan-Meier and Cox regression analyses to assess these outcomes stratified by antithrombotic regimen and adjusted for demographic, comorbid, clinical, and operative differences between the treatment groups with clustering at the center level. RESULTS: Among 1812 patients (median follow-up, >2 years), 693 (38%) were discharged with SAPT, 544 (30%) with DAPT, and 575 (32%) with AC+AP. At 3 years, the MALE rates were 75% with DAPT, 74% with AC+AP, and 68% with SAPT. In adjusted analyses with SAPT as the reference group, no differences were found in 3-year MALE with DAPT (adjusted hazard ratio [aHR], 1.0; 95% confidence interval [CI], 0.85-1.3; P = .71) or AC+AP (aHR, 1.1; 95% CI, 0.96-1.3; P = .14). Across the treatment groups, we also found no differences in the individual end points of 3-year major amputation (DAPT: aHR, 0.98; 95% CI, 0.72-1.3; AC+AP: aHR, 1.3; 95% CI, 0.96-1.7), reintervention (DAPT: aHR, 1.0; 95% CI, 0.84-1.3; AC+AP: aHR, 1.1; 95% CI, 0.96-1.3), or mortality (DAPT: aHR, 1.1; 95% CI, 0.88-1.4; AC+AP: aHR, 0.95; 95% CI, 0.74-1.2). In a sensitivity analysis evaluating patients treated by providers who discharged >60%, >70%, or >80% of patients with these regimens, the association between antithrombotic regimen and MALE was unchanged. CONCLUSIONS: Compared with SAPT, DAPT and anticoagulation therapy were not associated with improved outcomes among Medicare beneficiaries who had undergone infrapopliteal bypass for CLTI at VQI participating centers. These findings support current guidelines recommending SAPT after lower extremity bypass and suggest that the routine use of DAPT or anticoagulation therapy might not provide clinical benefit in this high-risk, elderly population. However, further evaluation of the risks and benefits of various antithrombotic regimens in relevant subgroups is warranted.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Marcaccio CL, Patel PB, Wang S, et al. Effect of postoperative antithrombotic therapy on lower extremity outcomes after infrapopliteal bypass for chronic limb-threatening ischemia. J Vasc Surg. 2022. PMID: 35074410. doi:10.1016/j.jvs.2022.01.011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。